⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52748 | 0.74 | — | — | |
| SCHEMBL1374067 | 0.74 | — | — | |
| SCHEMBL12483414 | 0.71 | — | — | |
| SCHEMBL2867903 | 0.70 | — | — | |
| SCHEMBL790684 | 0.70 | — | — | |
| SCHEMBL508305 | 0.70 | — | — | |
| SCHEMBL18399226 | 0.70 | — | — | |
| SCHEMBL8502472 | 0.70 | — | — | |
| SCHEMBL12483727 | 0.70 | — | — | |
| SCHEMBL749761 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | claimed |
| US-9365526-B2 | Process for the preparation of dasatinib and its intermediates | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-06-14 | — | — | US | claimed |
| US-20150336913-A1 | PROCESS FOR THE PREPARATION OF DASATINIB AND ITS INTERMEDIATES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-11-26 | — | — | US | claimed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | claimed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | claimed |
| WO-2014102759-A2 | PROCESS FOR THE PREPARATION OF DASATINIB AND ITS INTERMEDIATES | RANBAXY LABORATORIES LIMITED (IN) | 2014-07-03 | — | — | WO | claimed |
| CN-103649073-A | 17alpha-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2014-03-19 | — | — | CN | claimed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | claimed |
| CN-102838594-A | Preparation and refining method of dasatinib | NANJING SANHOME PHARMACEUTICAL CO LTD | 2012-12-26 | — | — | CN | claimed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | claimed |
| CN-102731413-A | Urea compound and its preparation method, intermediate and use | SHANGHAI INST PHARM INDUSTRY | 2012-10-17 | — | — | CN | claimed |
| CN-115340528-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2018137607-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018137593-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| EP-3325449-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-05-30 | — | — | EP | disclosed |
| EP-1689740-A1 | PYRAZOLYL AND IMIDAZOLYL PYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054231-A1 | PYRAZOLYL AND IMIDAZOLYL PYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| US-5981581-A | FOR CONTROLLING ANIMAL PESTS OR HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| US-5965587-A | PESTICIDES, FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| US-4753940-A | PARASITICIDE, ANTHELMINTIC | CIBA-GEIGY CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |